Global Cancer Biomarkers Market Assessment, By Type [Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers], By Technology [OMICS, Imaging Technology, Immunoassays, Cytogenetics, Bioinformatics, Others], By Cancer Type [Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Other Cancer], By Application [Diagnostics, Research and Development, Prognostics, Risk Assessment, Treatment, Other Applications], By End-user [Hospitals, Pharmaceutical and Biotechnological Companies, Diagnostic Laboratories, Cancer Research Institutes, Others], By Region, Opportunities and Forecast, 2017-2031F
The global cancer biomarkers market is expected to grow due to the increasing prevalence of varied cancers. The effectiveness of biomarkers for cancer detection propel the market players for continuous research and development in the market.
Home>Industry Reports>Global Cancer Biomarkers Market Assessment, Opportunities and Forecast, 2017-2031F
Global cancer biomarkers market size was valued at USD 15.1 billion in 2023, which is expected to reach USD 43.53 billion in 2031, with a CAGR of 14.15% for the forecast period between 2024 and 2031F. The global cancer biomarkers market is expected to grow due to the growing research environment around cancer biomarkers. Cancer biomarkers are a highly effective way of cancer detection as they offer precision diagnostics, since various market players are researching to find more effective and precise cancer biomarkers.
The number of cancer cases has significantly increased in recent years due to factors like genetic mutations, changing lifestyles, smoking, and alcohol consumption. Increasing cancer cases demand more precise and rapid screening methods, which foster market growth. The growing prevalence of cancer patients coupled with cutting-edge technologies is expected to fuel market growth. Factors such as the increasing prevalence of cancer patients, government initiatives, regulatory policies, and technological advancements are expected to fuel market growth.
In July 2023, Quest Diagnostics, the leading provider of diagnostic information services, announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. The new, tissue-based test service is intended to address the pressing clinical need for tests to help identify and differentiate potentially aggressive cases of prostate cancer in men. Such cutting-edge product approvals are expected to play a significant role in driving the global cancer biomarkers market.
Increasing Research and Development in Cancer Biomarkers
Cancer is one of the leading causes of death globally, without any exception in developed or developing countries. Cancer biomarkers have been significant contributors to cancer screening. Research institutes and market players are consistently involved in cancer biomarker research which is being supported by government authorities, investors, and regulatory bodies. Research is mainly focused on the identification, optimization, and utilization of different biomarkers to facilitate cancer diagnosis, research, and treatment. Thus, increasing investment by the government in research and development along with companies working in cancer biomarkers space are expected to fuel market growth.
In April 2023, a team led by Florida State University chemists developed a new test for detecting biological markers related to several types of cancer. The sensing platform is made of a gold nanoparticle and molecules called peptides that are labeled with a dye. Chemical bonds connect the components, while the gold nanoparticle restrains the dye from glowing in the presence of UV light. When a patient sample containing Enzyme MMP-14 (a cancer biomarker) is added to the preparation, the peptide bond is broken, separating a fragment with the dye from the gold. Without the gold to absorb the energy from the dye, the sample begins to glow, thus detecting the cancer presence.
Increasing Focus on Protein Biomarker
Protein biomarkers are gaining attention from healthcare professionals as well as patients for cancer screening. The reliability of the protein biomarker as a cancer predictor is of great significance if it is consistently expressed in cancer patients. Furthermore, the protein biomarker's widespread expression can facilitate its identification as a biomarker. Mass spectroscopy-based proteomics tools are utilized for the identification of cancer biomarkers. The increasing focus on protein biomarkers for cancer screening is expected to increase the market demand for protein biomarker-based cancer screenings.
In June 2023, Danish biomarker company Nordic Bioscience announced that its PRO-C3 biomarker assay had received a Letter of Support (LoS) from the United States Food and Drug Administration. PRO C3 is the world’s first blood-based tumor fibrosis biomarker based on protein biomarkers for patients with aggressive solid tumors. Regulatory approval of promising products in the global cancer biomarkers market is anticipated to contribute to market growth in forecast years.
Government Initiatives
Government initiatives such as providing research funding, drafting supportive policies, and promoting investments for new establishments are some of the major driving forces for the market. In the global cancer biomarkers market, government organizations, associations, and agencies actively promote cancer screening and treatments through awareness initiatives, thereby fostering the market growth. The governments of several countries are funding research projects addressing cancer diagnostic techniques.
According to a press release from The White House, in March 2023, the United States government invested USD 394.5 million in three CDC programs, National Comprehensive Cancer Control Program, National Breast and Cervical Cancer Early Detection Programs, and Colorectal Cancer Control Program to address the need of screening and treatment of most prevalent type of cancer. In June 2023, as part of the Cancer Moonshot Research Initiatives, the National Institutes of Health, the FNIH, and twelve top pharmaceutical companies announced the start of the five-year, USD 220 million Partnership for Accelerating Cancer Therapies (PACT). PACT is concentrated on finding, creating, and validating strong biomarkers to promote novel treatments and therapies that engage the immune system to combat cancer. The FDA has an advising role in the partnership, which the FNIH manages.
Impact of COVID-19
COVID-19 had a notable impact on the global cancer biomarkers market. During the pandemic COVID-19 patients were of highest priority for healthcare professionals and highlighted the significance of cancer diagnostics and early detection. Cancer biomarkers, which play a pivotal role in the identification of cancer and the monitoring of treatment responses, gained increased attention as healthcare systems worldwide recognized the importance of bolstering cancer care infrastructure. Despite some disruptions in routine cancer screening programs, the pandemic accelerated the adoption of telemedicine and remote monitoring, highlighting the potential for using biomarkers in novel ways. Moreover, the urgent need for more accurate and efficient diagnostic tools spurred research and development efforts in the field of cancer biomarkers. As healthcare systems and hospitals recovered from the pandemic’s disruptions, the global cancer biomarkers market saw strong growth, with an increased emphasis on early cancer detection and personalized treatment.
Report Scope
“Cancer Biomarkers Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global cancer biomarkers market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, COVID-19 impact, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
In this report, global cancer biomarkers market has been segmented into the following categories:
o Genetic Biomarkers
§ Breast Cancer Genetic Biomarkers
§ Colorectal Cancer Genetic Biomarkers
§ Leukemia Genetic Biomarkers
§ Lung Cancer Genetic Biomarkers
§ Prostate Cancer Genetic Biomarkers
§ Other Cancer Genetic Biomarkers
o Other Cancer Biomarkers
· By Technology
§ Proteomics
§ Genomics
ú Next Generation Sequencing (NGS)
ú Polymerase Chain Reaction (PCR)
ú Others
§ Other OMICS Technology
o Imaging Technology
§ Magnetic Resonance Imaging (MRI)
§ Computed Tomography (CT)
§ Positron Emission Tomography (PET)
§ Mammography
§ Ultrasound
o Immunoassays
o Bioinformatics
o Cytogenetics
§ In-situ Hybridization (ISH)
§ Other Cytogenetics Based Tests
o Lung Cancer
o Colorectal Cancer
o Melanoma
o Blood Cancer
o Prostate Cancer
o Ovarian Cancer
o Stomach Cancer
o Liver Cancer
o Other Cancers
· By Application
o Diagnostics
o Research and Development
o Prognostics
o Risk Assessment
o Treatment
o Other Applications
· By End-user
o Hospitals
o Pharmaceutical and Biotechnological Companies
o Diagnostic Laboratories
o Cancer Research Institutes
o Others
· By Region
o North America
o Europe
o Asia Pacific
o South America
o Middle East & Africa
Key Players Landscape and Outlook
Market players are employing a range of strategies to increase their product offerings and give customers access to a wide selection of innovative products. Additionally, companies are expanding the range of diagnostic services offered to capture a bigger portion of the market. Many major industry players are using various growth techniques, like partnerships, mergers and acquisitions, development and launch of new goods, to strengthen their position in the worldwide market.
In September 2023, Ibex launched Galen Breast HER2, an AI-powered solution that helps pathologists for accurate and reproducible biomarker scoring in breast cancer patients. Ibex's Galen Breast HER2 is an AI-powered HER2 receptor scoring system that detects and quantifies the HER2 expression in breast cancer cases and scores it based on 2018 ASCO/CAP scoring guidelines. It can be utilized in screening and checking the effectiveness of treatment being provided to breast cancer patients.
Key Players Operating in the Global Cancer Biomarkers Market are:
· Abbott
· Thermo Fisher Scientific Inc.
· Illumina, Inc.
· QIAGEN
· F. Hoffmann-La Roche Ltd
· Agilent Technologies, Inc.
· Quest Diagnostics Incorporated
· Merck KGaA
· Hologic, Inc.
· Bio-Rad Laboratories
Markets and Data report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global cancer biomarkers market, you may approach our team at info@marketsandata.com.
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Impact of COVID-19 on Global Cancer Biomarkers Market
4. Executive Summary
5. Global Cancer Biomarkers Market Outlook, 2017-2031F
5.1 Market Size & Forecast
5.1.1 By Value
5.1.2 By Volume
5.2 By Type
5.2.1 Protein Biomarkers
5.2.2 Genetic Biomarkers
5.2.2.1 Breast Cancer Genetic Biomarkers
5.2.2.2 Colorectal Cancer Genetic Biomarkers
5.2.2.3 Leukemia Genetic Biomarkers
5.2.2.4 Lung Cancer Genetic Biomarkers
5.2.2.5 Prostate Cancer Genetic Biomarkers
5.2.2.6 Other Cancer Genetic Biomarkers
5.2.3 Other Cancer Biomarkers
5.3 By Technology
5.3.1 OMICS
5.3.1.1 Proteomics
5.3.1.2 Genomics
5.3.1.2.1 Next Generation Sequencing (NGS)
5.3.1.2.2 Polymerase Chain Reaction (PCR)
5.3.1.2.3 Others
5.3.1.3 Other OMICS Technology
5.3.2 Imaging Technology
5.3.2.1 Magnetic Resonance Imaging (MRI)
5.3.2.2 Computed Tomography (CT)
5.3.2.3 Positron Emission Tomography (PET)
5.3.2.4 Mammography
5.3.2.5 Ultrasound
5.3.3 Immunoassays
5.3.4 Bioinformatics
5.3.5 Cytogenetics
5.3.5.1 In-situ Hybridization (ISH)
5.3.5.2 Other Cytogenetics Based Tests
5.4 By Cancer Type
5.4.1 Breast Cancer
5.4.2 Lung Cancer
5.4.3 Colorectal Cancer
5.4.4 Melanoma
5.4.5 Blood Cancer
5.4.6 Prostate Cancer
5.4.7 Ovarian Cancer
5.4.8 Stomach Cancer
5.4.9 Liver Cancer
5.4.10 Other Cancer
5.5 By Application
5.5.1 Diagnostics
5.5.2 Research and Development
5.5.3 Prognostics
5.5.4 Risk Assessment
5.5.5 Treatment
5.5.6 Other Applications
5.6 By End-user
5.6.1 Pharmaceutical and Biotechnological Companies
5.6.2 Diagnostic Laboratories
5.6.3 Cancer Research Institutes
5.6.4 Others
5.7 By Region
5.7.1 North America
5.7.2 Europe
5.7.3 Asia Pacific
5.7.4 South America
5.7.5 Middle East & Africa
5.8 By Company Market Share (%), 2023
6. Global Cancer Biomarkers Market Outlook, 2017-2031F
6.1. North America*
6.1.1.Market Size & Forecast
6.1.1.1. By Value
6.1.1.2. By Volume
6.1.2. By Type
6.1.2.1. Protein Biomarkers
6.1.2.2. Genetic Biomarkers
6.1.2.2.1. Breast Cancer Genetic Biomarkers
6.1.2.2.2. Colorectal Cancer Genetic Biomarkers
6.1.2.2.3. Leukemia Genetic Biomarkers
6.1.2.2.4. Lung Cancer Genetic Biomarkers
6.1.2.2.5. Prostate Cancer Genetic Biomarkers
6.1.2.2.6. Other Cancer Genetic Biomarkers
6.1.2.3. Other Cancer Biomarkers
6.1.3.By Technology
6.1.3.1. OMICS
6.1.3.1.1. Proteomics
6.1.3.1.2. Genomics
6.1.3.1.2.1. Next Generation Sequencing (NGS)
6.1.3.1.2.2. Polymerase Chain Reaction (PCR)
6.1.3.1.2.3. Others
6.1.3.1.3. Other OMICS Technology
6.1.3.2. Imaging Technology
6.1.3.2.1. Magnetic Resonance Imaging (MRI)
6.1.3.2.2. Computed Tomography (CT)
6.1.3.2.3. Positron Emission Tomography (PET)
6.1.3.2.4. Mammography
6.1.3.2.5. Ultrasound
6.1.3.3. Immunoassays
6.1.3.4. Bioinformatics
6.1.3.5. Cytogenetics
6.1.3.5.1. In-situ Hybridization (ISH)
6.1.3.5.2. Other Cytogenetics Based Tests
6.1.4.By Cancer Type
6.1.4.1. Breast Cancer
6.1.4.2. Lung Cancer
6.1.4.3. Colorectal Cancer
6.1.4.4. Melanoma
6.1.4.5. Blood Cancer
6.1.4.6. Prostate Cancer
6.1.4.7. Ovarian Cancer
6.1.4.8. Stomach Cancer
6.1.4.9. Liver Cancer
6.1.4.10. Other Cancer
6.1.5.By Application
6.1.5.1. Diagnostics
6.1.5.2. Research and Development
6.1.5.3. Prognostics
6.1.5.4. Risk Assessment
6.1.5.5. Treatment
6.1.5.6. Other Applications
6.1.6.By End-user
6.1.6.1. Hospitals
6.1.6.2. Pharmaceutical and Biotechnological Companies
6.1.6.3. Diagnostic Laboratories
6.1.6.4. Cancer Research Institutes
6.1.6.5. Others
6.1.7.United States*
6.1.7.1. Market Size & Forecast
6.1.7.1.1. By Value
6.1.7.1.2. By Volume
6.1.7.2. By Type
6.1.7.2.1. Protein Biomarkers
6.1.7.2.2. Genetic Biomarkers
6.1.7.2.2.1. Breast Cancer Genetic Biomarkers
6.1.7.2.2.2. Colorectal Cancer Genetic Biomarkers
6.1.7.2.2.3. Leukemia Genetic Biomarkers
6.1.7.2.2.4. Lung Cancer Genetic Biomarkers
6.1.7.2.2.5. Prostate Cancer Genetic Biomarkers
6.1.7.2.2.6. Other Cancer Genetic Biomarkers
6.1.7.2.3. Other Cancer Biomarkers
6.1.7.3. By Technology
6.1.7.3.1. OMICS
6.1.7.3.1.1. Proteomics
6.1.7.3.1.2. Genomics
6.1.7.3.1.2.1. Next Generation Sequencing (NGS)
6.1.7.3.1.2.2. Polymerase Chain Reaction (PCR)
6.1.7.3.1.2.3. Others
6.1.7.3.1.3. Other OMICS Technology
6.1.7.3.2. Imaging Technology
6.1.7.3.2.1. Magnetic Resonance Imaging (MRI)
6.1.7.3.2.2. Computed Tomography (CT)
6.1.7.3.2.3. Positron Emission Tomography (PET)
6.1.7.3.2.4. Mammography
6.1.7.3.2.5. Ultrasound
6.1.7.3.3. Immunoassays
6.1.7.3.4. Bioinformatics
6.1.7.3.5. Cytogenetics
6.1.7.3.5.1. In-situ Hybridization (ISH)
6.1.7.3.5.2. Other Cytogenetics Based Tests
6.1.7.4. By Cancer Type
6.1.7.4.1. Breast Cancer
6.1.7.4.2. Lung Cancer
6.1.7.4.3. Colorectal Cancer
6.1.7.4.4. Melanoma
6.1.7.4.5. Blood Cancer
6.1.7.4.6. Prostate Cancer
6.1.7.4.7. Ovarian Cancer
6.1.7.4.8. Stomach Cancer
6.1.7.4.9. Liver Cancer
6.1.7.4.10. Other Cancer
6.1.7.5. By Application
6.1.7.5.1. Diagnostics
6.1.7.5.2. Research and Development
6.1.7.5.3. Prognostics
6.1.7.5.4. Risk Assessment
6.1.7.5.5. Treatment
6.1.7.5.6. Other Applications
6.1.7.6. By End-user
6.1.7.7. Hospitals
6.1.7.8. Pharmaceutical and Biotechnological Companies
6.1.7.9. Diagnostic Laboratories
6.1.7.10. Cancer Research Institutes
6.1.7.11. Others
6.1.8.Canada
6.1.9.Mexico
*All segments will be provided for all regions and countries covered
6.2. Europe
6.2.1.Germany
6.2.2.France
6.2.3.Italy
6.2.4.United Kingdom
6.2.5.Russia
6.2.6.Netherlands
6.2.7.Spain
6.2.8.Turkey
6.2.9.Poland
6.3. South America
6.3.1.Brazil
6.3.2.Argentina
6.4. Asia-Pacific
6.4.1.India
6.4.2.China
6.4.3.Japan
6.4.4.Australia
6.4.5.Vietnam
6.4.6.South Korea
6.4.7.Indonesia
6.4.8.Philippines
6.5. Middle East & Africa
6.5.1.Saudi Arabia
6.5.2.UAE
6.5.3.South Africa
7. Market Mapping, 2023
7.1. By Type
7.2. By Technology
7.3. By Cancer Type
7.4. By Application
7.5. By End-user
7.6. By Region
8. Macro Environment and Industry Structure
8.1. Supply Demand Analysis
8.2. Import Export Analysis – Volume and Value
8.3. Supply/Value Chain Analysis
8.4. PESTEL Analysis
8.4.1.Political Factors
8.4.2.Economic System
8.4.3.Social Implications
8.4.4.Technological Advancements
8.4.5.Environmental Impacts
8.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.5. Porter’s Five Forces Analysis
8.5.1.Supplier Power
8.5.2.Buyer Power
8.5.3.Substitution Threat
8.5.4.Threat from New Entrant
8.5.5.Competitive Rivalry
9. Market Dynamics
9.1. Growth Drivers
9.2. Growth Inhibitors (Challenges, Restraints)
10. Regulatory Framework and Innovation
10.1. Clinical Trials
10.2. Patent Landscape
10.3. Regulatory Approvals
10.4. Innovations/Emerging Technologies
11. Key Players Landscape
11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)
12. Pricing Analysis
13. Case Studies
14. Key Players Outlook
14.1. Abbott
14.1.1. Company Details
14.1.2. Key Management Personnel
14.1.3. Products & Services
14.1.4. Financials (As reported)
14.1.5. Key Market Focus & Geographical Presence
14.1.6. Recent Developments
14.2. Thermo Fisher Scientific Inc.
14.3. Illumina, Inc.
14.4. QIAGEN
14.5. F. Hoffmann-La Roche Ltd
14.6. Agilent Technologies, Inc.
14.7. Quest Diagnostics Incorporated
14.8. Merck KGaA
14.9. Hologic, Inc.
14.10. Bio-Rad Laboratories
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
15. Strategic Recommendations
16. About Us & Disclaimer
List of Figures
Figure 1. Global Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 3. Global Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 4. Global Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 5. Global Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 6. Global Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 7. Global Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 8. Global Cancer Biomarkers Market Share (%), By Region, 2017-2031F
Figure 9. North America Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 10. North America Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 11. North America Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 12. North America Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 13. North America Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 14. North America Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 15. North America Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 16. North America Cancer Biomarkers Market Share (%), By Country, 2017-2031F
Figure 17. United States Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 18. United States Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 19. United States Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 20. United States Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 21. United States Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 22. United States Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 23. United States Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 24. Canada Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 25. Canada Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 26. Canada Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 27. Canada Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 28. Canada Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 29. Canada Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 30. Canada Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 31. Mexico Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 32. Mexico Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 33. Mexico Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 34. Mexico Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 35. Mexico Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 36. Mexico Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 37. Mexico Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 38. Europe Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 39. Europe Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 40. Europe Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 41. Europe Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 42. Europe Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 43. Europe Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 44. Europe Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 45. Europe Cancer Biomarkers Market Share (%), By Country, 2017-2031F
Figure 46. Germany Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 47. Germany Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 48. Germany Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 49. Germany Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 50. Germany Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 51. Germany Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 52. Germany Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 53. France Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 54. France Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 55. France Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 56. France Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 57. France Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 58. France Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 59. France Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 60. Italy Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 61. Italy Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 62. Italy Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 63. Italy Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 64. Italy Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 65. Italy Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 66. Italy Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 67. United Kingdom Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 68. United Kingdom Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 69. United Kingdom Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 70. United Kingdom Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 71. United Kingdom Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 72. United Kingdom Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 73. United Kingdom Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 74. Russia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 75. Russia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 76. Russia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 77. Russia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 78. Russia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 79. Russia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 80. Russia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 81. Netherlands Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 82. Netherlands Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 83. Netherlands Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 84. Netherlands Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 85. Netherlands Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 86. Netherlands Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 87. Netherlands Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 88. Spain Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 89. Spain Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 90. Spain Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 91. Spain Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 92. Spain Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 93. Spain Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 94. Spain Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 95. Turkey Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 96. Turkey Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 97. Turkey Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 98. Turkey Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 99. Turkey Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 100. Turkey Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 101. Turkey Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 102. Poland Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 103. Poland Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 104. Poland Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 105. Poland Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 106. Poland Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 107. Poland Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 108. Poland Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 109. South America Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 110. South America Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 111. South America Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 112. South America Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 113. South America Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 114. South America Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 115. South America Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 116. South America Cancer Biomarkers Market Share (%), By Country, 2017-2031F
Figure 117. Brazil Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 118. Brazil Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 119. Brazil Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 120. Brazil Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 121. Brazil Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 122. Brazil Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 123. Brazil Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 124. Argentina Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 125. Argentina Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 126. Argentina Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 127. Argentina Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 128. Argentina Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 129. Argentina Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 130. Argentina Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 131. Asia-Pacific Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 132. Asia-Pacific Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 133. Asia-Pacific Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 134. Asia-Pacific Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 135. Asia-Pacific Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 136. Asia-Pacific Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 137. Asia- Pacific Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 138. Asia-Pacific Cancer Biomarkers Market Share (%), By Country, 2017-2031F
Figure 139. India Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 140. India Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 141. India Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 142. India Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 143. India Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 144. India Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 145. India Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 146. China Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 147. China Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 148. China Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 149. China Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 150. China Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 151. China Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 152. China Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 153. Japan Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 154. Japan Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 155. Japan Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 156. Japan Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 157. Japan Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 158. Japan Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 159. Japan Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 160. Australia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 161. Australia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 162. Australia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 163. Australia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 164. Australia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 165. Australia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 166. Australia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 167. Vietnam Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 168. Vietnam Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 169. Vietnam Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 170. Vietnam Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 171. Vietnam Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 172. Vietnam Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 173. Vietnam Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 174. South Korea Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 175. South Korea Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 176. South Korea Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 177. South Korea Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 178. South Korea Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 179. South Korea Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 180. South Korea Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 181. Indonesia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 182. Indonesia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 183. Indonesia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 184. Indonesia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 185. Indonesia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 186. Indonesia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 187. Indonesia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 188. Philippines Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 189. Philippines Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 190. Philippines Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 191. Philippines Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 192. Philippines Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 193. Philippines Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 194. Philippines Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 195. Middle East & Africa Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 196. Middle East & Africa Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 197. Middle East & Africa Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 198. Middle East & Africa Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 199. Middle East & Africa Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 200. Middle East & Africa Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 201. Middle East & Africa Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 202. Middle East & Africa Cancer Biomarkers Market Share (%), By Country, 2017-2031F
Figure 203. Saudi Arabia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 204. Saudi Arabia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 205. Saudi Arabia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 206. Saudi Arabia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 207. Saudi Arabia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 208. Saudi Arabia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 209. Saudi Arabia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 210. UAE Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 211. UAE Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 212. UAE Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 213. UAE Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 214. UAE Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 215. UAE Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 216. UAE Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 217. South Africa Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
Figure 218. South Africa Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
Figure 219. South Africa Cancer Biomarkers Market Share (%), By Type, 2017-2031F
Figure 220. South Africa Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
Figure 221. South Africa Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
Figure 222. South Africa Cancer Biomarkers Market Share (%), By Application, 2017-2031F
Figure 223. South Africa Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
Figure 224. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 225. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 226. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 227. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What are the major drivers influencing the growth of the global cancer biomarkers market?
What regions are covered in the final report for global cancer biomarkers market?
Who are the key players operating in global cancer biomarkers market?
What is the market size and growth rate of the global cancer biomarkers market?
See Related Reports
Global Coffee Market Assessment, Opportunities and Forecast, 2017-2031F
Global coffee market is expected to experience growth due to consumers’ increasing preference for organic and premium coffee that offers freshness, superior quality of beans and roasts, and unique flavor profile. Additionally, the product innovation,....Read More
Published on
July 2024
4,500
Global Home Theater System Market Assessment, Opportunities and Forecast, 2017-2031F
Global home theater system market is expected to experience growth due to technological advancements, increasing disposable incomes, rising demand for high-definition content, integration with smart home systems, and the surge in streaming services p....Read More
Published on
July 2024
4,500
Global Baby Food Market Assessment, Opportunities and Forecast, 2017-2031F
Global baby food market is expected to experience growth due to factors such as consumers’ increasing awareness of the nutrients which are essential for babies development and introduction of wide variety of baby foods in the market from milk powders....Read More
Published on
July 2024
4,500
Global Isoflavones Market Assessment, Opportunities and Forecast, 2017-2031F
Global isoflavones market is expected to experience growth due to increasing consumer health awareness, rising demand for functional foods and nutraceuticals, advancements in extraction technologies, and expanding applications in cosmetics, pharmaceu....Read More
Published on
July 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
